7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,858.09

+492.46

+0.64%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCQB - Delayed Quote USD

Medicenna Therapeutics Corp. (MDNAF)

0.3110 -0.0370 (-10.63%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for MDNAF

Chart Range Bar

Interval:

In partnership with ChartIQ

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Mobilize your Website

View Site in Mobile | Classic

Share by: